Léa Perles

90% of patients with solid tumors relapse under treatment (chemotherapy or conventional immunotherapy), leading to the death of more than 10 million people worldwide in 2024. The main reason is that cancer is a moving, heterogeneous and invisible target. For many patients, the immune system is blinded by cancer plasticity, resulting in no anti-tumor response being initiated and an inefficiency of classical immunotherapy. Brenus Pharma is a French clinical-stage biotech developing a new modality in in vivo immunotherapies for solid tumors, derived from a fully off-the-shelf platform. This proprietary platform, Stimulated Ghost Cell (SGC), reproduces tumor protein expression and makes these targets visible to the immune system, enabling broad, multi-specific responses against heterogeneous and evolving tumors.Brenus platform is standardized, GMP-ready, applying precision medicine principles at a large scale, aiming to answer patients’ medical needs, control time and costs of supply, and reach broader patient populations where personalized therapies remain limited. The lead candidate, STC-1010, targets metastatic colorectal cancer and is currently in a Phase I/II trial (NCT06934538), with several active centers across France and Belgium.